Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 3.93B | 4.04B | 3.61B | 2.82B | 3.19B |
| Total Depreciation and Amortization | 1.26B | 1.16B | 1.15B | 165.00M | 1.16B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 320.00M | 1.30B | 894.00M | 1.47B | 1.11B |
| Change in Net Operating Assets | 1.06B | 163.00M | -2.01B | -255.00M | 824.00M |
| Cash from Operations | 6.57B | 6.66B | 3.65B | 4.19B | 6.29B |
| Capital Expenditure | -354.00M | -331.00M | -254.00M | -558.00M | -321.00M |
| Sale of Property, Plant, and Equipment | 1.00M | 1.00M | 10.00M | 47.00M | 1.00M |
| Cash Acquisitions | 1.00M | -1.66B | -- | -426.00M | -58.00M |
| Divestitures | -64.00M | -11.00M | -4.00M | 164.00M | 7.00M |
| Other Investing Activities | -444.00M | -238.00M | 578.00M | -2.26B | -3.00M |
| Cash from Investing | -860.00M | -2.24B | 330.00M | -3.03B | -374.00M |
| Total Debt Issued | 135.00M | 850.00M | 556.00M | -24.00M | 3.67B |
| Total Debt Repaid | -646.00M | -669.00M | -1.08B | -82.00M | -1.16B |
| Issuance of Common Stock | 2.00M | 20.00M | 1.00M | 0.00 | 5.00M |
| Repurchase of Common Stock | -2.30B | -2.71B | -2.72B | -2.76B | -2.85B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -2.49B | -5.33B | 0.00 | -- |
| Other Financing Activities | 22.00M | -215.00M | 23.00M | -128.00M | -43.00M |
| Cash from Financing | -2.79B | -5.21B | -8.55B | -3.00B | -382.00M |
| Foreign Exchange rate Adjustments | -22.00M | 382.00M | 180.00M | -314.00M | 176.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.90B | -410.00M | -4.39B | -2.15B | 5.71B |